Case Report: Findings Suggestive of Paraclinical Progressive Multifocal Leukoencephalopathy and Lung Cancer-Derived Brain Metastases in an MS Patient Treated With Fingolimod
Fingolimod represents a highly effective disease-modifying drug in patients with active relapsing-remitting multiple sclerosis (RRMS). Its immunosuppressive effects can mediate adverse events like increased risk of cancer development or appearance of opportunistic infections. Progressive multifocal...
Main Authors: | Fabian Maass, Philipp von Gottberg, Jonas Franz, Christine Stadelmann, Mathias Bähr, Martin S. Weber |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2021.561158/full |
Similar Items
-
Acute Anterior Uveitis in a Patient Taking Fingolimod (FTY720) for Multiple Sclerosis
by: Heather Gwen Mack, et al.
Published: (2016-12-01) -
Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis
by: Vahid Shaygannezhad, et al.
Published: (2017-08-01) -
Fingolimod Modulates Dendritic Architecture in a BDNF-Dependent Manner
by: Abhisarika Patnaik, et al.
Published: (2020-04-01) -
Fingolimod (FTY720) Tedavisinin Relapsing-Remitting Multipl Skleroz Hastalarında Karaciğer Enzim Düzeylerine Etkisi
by: Duygu Tap, et al.
Published: (2020-12-01) -
Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French Center
by: Thomas Roux, et al.
Published: (2017-05-01)